{"id":{"repo_id":"uiuc","oai_identifier":"oai:www.ideals.illinois.edu:2142/26297"},"canonical_url":"https://search.dev.ndltd.org/etd/uiuc/oai:www.ideals.illinois.edu:2142/26297","repository":{"repo_id":"uiuc","name":"University of Illinois - Urbana-Champaign","base_url":"https://www.ideals.illinois.edu/oai-pmh"},"display":{"title":"Engineering of an efficient and enantioselective biocatalyst for the preparation of chiral pharmaceutical intermediates","abstract":"This Ph.D. thesis focuses on the engineering of an efficient and enantioselective biocatalyst via direct evolution and genetic engineering for the enantioselective hydroxylation of non-activated carbon atom, a useful but challenging reaction for the synthesis of chiral pharmaceutical intermediates. Our target enzyme is the novel P450pyr enzyme from Sphingomonas sp. HXN-200 that was found to catalyze the regio- and stereoselective hydroxylation of non-activated carbon atom with broad substrate range, high activity, excellent regioselectivity, and good to excellent enantioselectivity. Our target reaction is the enzymatic hydroxylation of N-benzyl pyrrolidine to its corresponding (R)- and (S)-N-benzyl-3-hydroxypyrrolidines which are important pharmaceutical intermediates. In this thesis, a two-enzyme-based colorimetric high-throughput ee screening assay and a mass spectrometry-based high-throughput ee screening assay were developed. The P450pyr monooxygenase was engineered by directed evolution for the enantioselective hydroxylation of N-benzyl pyrrolidine. Several mutants exhibiting increased and/or inverted enantioselectivity were identified, with product ee of 83% (R) and 65% (S) for mutants 1AF4A and 11BB12, respectively. The wild type P450pyr and its mutants were also purified and reconstituted with their auxiliary electron transport proteins, ferredoxin and ferredoxin reductase in vitro. The mutants were then used to catalyze the hydroxylations of a range of different substrates using whole-cell assays to investigate the changes in product ee. In addition, an efficient biocatalytic system with cofactor recycling was developed by co-expressing a glucose dehydrogenase from Bacillus substilis or a phosphite dehydrogenase from Pseudomonas stutzeri together with the P450pyr system in a recombinant Escherichia coli.","abstract_html":"This Ph.D. thesis focuses on the engineering of an efficient and enantioselective biocatalyst via direct evolution and genetic engineering for the enantioselective hydroxylation of non-activated carbon atom, a useful but challenging reaction for the synthesis of chiral pharmaceutical intermediates. Our target enzyme is the novel P450pyr enzyme from Sphingomonas sp. HXN-200 that was found to catalyze the regio- and stereoselective hydroxylation of non-activated carbon atom with broad substrate range, high activity, excellent regioselectivity, and good to excellent enantioselectivity. Our target reaction is the enzymatic hydroxylation of N-benzyl pyrrolidine to its corresponding (R)- and (S)-N-benzyl-3-hydroxypyrrolidines which are important pharmaceutical intermediates. In this thesis, a two-enzyme-based colorimetric high-throughput ee screening assay and a mass spectrometry-based high-throughput ee screening assay were developed. The P450pyr monooxygenase was engineered by directed evolution for the enantioselective hydroxylation of N-benzyl pyrrolidine. Several mutants exhibiting increased and/or inverted enantioselectivity were identified, with product ee of 83% (R) and 65% (S) for mutants 1AF4A and 11BB12, respectively. The wild type P450pyr and its mutants were also purified and reconstituted with their auxiliary electron transport proteins, ferredoxin and ferredoxin reductase in vitro. The mutants were then used to catalyze the hydroxylations of a range of different substrates using whole-cell assays to investigate the changes in product ee. In addition, an efficient biocatalytic system with cofactor recycling was developed by co-expressing a glucose dehydrogenase from Bacillus substilis or a phosphite dehydrogenase from Pseudomonas stutzeri together with the P450pyr system in a recombinant Escherichia coli.","abstract_has_math":false,"creators":["Tang, Weng Lin"],"institution":"University of Illinois at Urbana-Champaign","degree_name":"Ph.D.","degree_level":"Dissertation","degree_discipline":"Chemical Engineering","degree_department":null,"school":null,"contributors":["Zhao, Huimin","Chen, Shing Bor","Li, Zhi","Rao, Christopher V.","Gunawan, Rudiyanto"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2011,"date_issued":"2011-08-26T15:21:54Z","date_published":"2011-08-26T15:21:54Z","updated_at":"2026-07-22T22:25:26Z","subjects":["Directed Evolution","P450","High throughput screening","protein engineering"],"languages":["en"],"rights":["Copyright 2011 Weng Lin Tang"],"rights_urls":[],"identifier_entries":[]},"links":{"outbound_url":"http://hdl.handle.net/2142/26297","outbound_label":"Handle","outbound_source":"dc:identifier"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Zhao, Huimin","Chen, Shing Bor","Li, Zhi","Rao, Christopher V.","Gunawan, Rudiyanto"]},{"key":"dc:creator","label":"Author","values":["Tang, Weng Lin"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2011-08-26T15:21:54Z","2013-08-27T10:00:21Z","2011-08"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Chemical Engineering"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Dissertation"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Ph.D."]},{"key":"thesis:institution_name","label":"Thesis Institution Name","values":["University of Illinois at Urbana-Champaign"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Directed Evolution","P450","High throughput screening","protein engineering"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language","label":"Dc Language","values":["en"]},{"key":"dc:rights","label":"Dc Rights","values":["Copyright 2011 Weng Lin Tang"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["http://hdl.handle.net/2142/26297"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["This Ph.D. thesis focuses on the engineering of an efficient and enantioselective biocatalyst via direct evolution and genetic engineering for the enantioselective hydroxylation of non-activated carbon atom, a useful but challenging reaction for the synthesis of chiral pharmaceutical intermediates. Our target enzyme is the novel P450pyr enzyme from Sphingomonas sp. HXN-200 that was found to catalyze the regio- and stereoselective hydroxylation of non-activated carbon atom with broad substrate range, high activity, excellent regioselectivity, and good to excellent enantioselectivity. Our target reaction is the enzymatic hydroxylation of N-benzyl pyrrolidine to its corresponding (R)- and (S)-N-benzyl-3-hydroxypyrrolidines which are important pharmaceutical intermediates. In this thesis, a two-enzyme-based colorimetric high-throughput ee screening assay and a mass spectrometry-based high-throughput ee screening assay were developed. The P450pyr monooxygenase was engineered by directed evolution for the enantioselective hydroxylation of N-benzyl pyrrolidine. Several mutants exhibiting increased and/or inverted enantioselectivity were identified, with product ee of 83% (R) and 65% (S) for mutants 1AF4A and 11BB12, respectively. The wild type P450pyr and its mutants were also purified and reconstituted with their auxiliary electron transport proteins, ferredoxin and ferredoxin reductase in vitro. The mutants were then used to catalyze the hydroxylations of a range of different substrates using whole-cell assays to investigate the changes in product ee. In addition, an efficient biocatalytic system with cofactor recycling was developed by co-expressing a glucose dehydrogenase from Bacillus substilis or a phosphite dehydrogenase from Pseudomonas stutzeri together with the P450pyr system in a recombinant Escherichia coli.","Item withdrawn by Mark Zulauf (zulauf@illinois.edu) on 2011-05-11T18:38:41Z Item was in collections: University of Illinois Theses & Dissertations (ID: 1) No. of bitstreams: 1 Tang_WengLin.pdf: 2441176 bytes, checksum: c5745b21ebe6d25ee1c3f515404d190d (MD5)","Made available in DSpace on 2011-08-26T15:21:54Z (GMT). No. of bitstreams: 2 Tang_WengLin.pdf: 2435422 bytes, checksum: 867910cf0f92379bd9d3ebcba86026ad (MD5) license.txt: 4057 bytes, checksum: 280b1223f62103c0a8ea5b04bf6297ca (MD5)","Item marked as restricted to the 'UIUC Users [automated]' Group (id=2) by William Ingram (wingram2@illinois.edu) on 2011-08-26T15:25:47Z Item is restricted until 2013-08-26T15:25:28Z","Item reinstated by Sarah Shreeves (sshreeve@illinois.edu) on 2013-08-27T10:00:21Z Item was in collections: University of Illinois Dissertations and Theses (ID: 204) Dissertations and Theses - Chemical and Biomolecular Engineering (ID: 591) No. of bitstreams: 3 Tang_WengLin.pdf.txt: 259037 bytes, checksum: 5226c7555bb9678fa3b537b319b60f04 (MD5) Tang_WengLin.pdf: 2435422 bytes, checksum: 867910cf0f92379bd9d3ebcba86026ad (MD5) license.txt: 4057 bytes, checksum: 280b1223f62103c0a8ea5b04bf6297ca (MD5)","Item released from any restrictions by Sarah Shreeves (sshreeve@illinois.edu) on 2013-08-27T10:00:21Z"]},{"key":"dc:title","label":"Title","values":["Engineering of an efficient and enantioselective biocatalyst for the preparation of chiral pharmaceutical intermediates"]}]}],"canonical_facts":{"dc:contributor":["Zhao, Huimin","Chen, Shing Bor","Li, Zhi","Rao, Christopher V.","Gunawan, Rudiyanto"],"dc:creator":["Tang, Weng Lin"],"dc:date":["2011-08-26T15:21:54Z","2013-08-27T10:00:21Z","2011-08"],"dc:description":["This Ph.D. thesis focuses on the engineering of an efficient and enantioselective biocatalyst via direct evolution and genetic engineering for the enantioselective hydroxylation of non-activated carbon atom, a useful but challenging reaction for the synthesis of chiral pharmaceutical intermediates. Our target enzyme is the novel P450pyr enzyme from Sphingomonas sp. HXN-200 that was found to catalyze the regio- and stereoselective hydroxylation of non-activated carbon atom with broad substrate range, high activity, excellent regioselectivity, and good to excellent enantioselectivity. Our target reaction is the enzymatic hydroxylation of N-benzyl pyrrolidine to its corresponding (R)- and (S)-N-benzyl-3-hydroxypyrrolidines which are important pharmaceutical intermediates. In this thesis, a two-enzyme-based colorimetric high-throughput ee screening assay and a mass spectrometry-based high-throughput ee screening assay were developed. The P450pyr monooxygenase was engineered by directed evolution for the enantioselective hydroxylation of N-benzyl pyrrolidine. Several mutants exhibiting increased and/or inverted enantioselectivity were identified, with product ee of 83% (R) and 65% (S) for mutants 1AF4A and 11BB12, respectively. The wild type P450pyr and its mutants were also purified and reconstituted with their auxiliary electron transport proteins, ferredoxin and ferredoxin reductase in vitro. The mutants were then used to catalyze the hydroxylations of a range of different substrates using whole-cell assays to investigate the changes in product ee. In addition, an efficient biocatalytic system with cofactor recycling was developed by co-expressing a glucose dehydrogenase from Bacillus substilis or a phosphite dehydrogenase from Pseudomonas stutzeri together with the P450pyr system in a recombinant Escherichia coli.","Item withdrawn by Mark Zulauf (zulauf@illinois.edu) on 2011-05-11T18:38:41Z Item was in collections: University of Illinois Theses & Dissertations (ID: 1) No. of bitstreams: 1 Tang_WengLin.pdf: 2441176 bytes, checksum: c5745b21ebe6d25ee1c3f515404d190d (MD5)","Made available in DSpace on 2011-08-26T15:21:54Z (GMT). No. of bitstreams: 2 Tang_WengLin.pdf: 2435422 bytes, checksum: 867910cf0f92379bd9d3ebcba86026ad (MD5) license.txt: 4057 bytes, checksum: 280b1223f62103c0a8ea5b04bf6297ca (MD5)","Item marked as restricted to the 'UIUC Users [automated]' Group (id=2) by William Ingram (wingram2@illinois.edu) on 2011-08-26T15:25:47Z Item is restricted until 2013-08-26T15:25:28Z","Item reinstated by Sarah Shreeves (sshreeve@illinois.edu) on 2013-08-27T10:00:21Z Item was in collections: University of Illinois Dissertations and Theses (ID: 204) Dissertations and Theses - Chemical and Biomolecular Engineering (ID: 591) No. of bitstreams: 3 Tang_WengLin.pdf.txt: 259037 bytes, checksum: 5226c7555bb9678fa3b537b319b60f04 (MD5) Tang_WengLin.pdf: 2435422 bytes, checksum: 867910cf0f92379bd9d3ebcba86026ad (MD5) license.txt: 4057 bytes, checksum: 280b1223f62103c0a8ea5b04bf6297ca (MD5)","Item released from any restrictions by Sarah Shreeves (sshreeve@illinois.edu) on 2013-08-27T10:00:21Z"],"dc:identifier":["http://hdl.handle.net/2142/26297"],"dc:language":["en"],"dc:rights":["Copyright 2011 Weng Lin Tang"],"dc:subject":["Directed Evolution","P450","High throughput screening","protein engineering"],"dc:title":["Engineering of an efficient and enantioselective biocatalyst for the preparation of chiral pharmaceutical intermediates"],"thesis:degree_discipline":["Chemical Engineering"],"thesis:degree_level":["Dissertation"],"thesis:degree_name":["Ph.D."],"thesis:institution_name":["University of Illinois at Urbana-Champaign"]},"updated_at":"2026-07-22T22:25:26Z"}